Price
$1.66
Decreased by -4.60%
Dollar Volume
10.47 M
ADR%
24.56
Earnings Report Date (estimate)
Nov 15, 22 (-0.37)
Market Cap.
37.46 M
Shares Float
20.06 M
Shares Outstanding
22.57 M
Beta
0.00
Price / Earnings
0.00
BPR
2.34
20D Range
0.61 2.88
50D Range
0.61 2.88
200D Range
0.61 31.35
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 15, 22 -0.41 -0.28
Decreased by -46.43%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-8.49 M
Decreased by -11.37 K%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-1.67 B
Decreased by -494.09%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-9.04 M
Decreased by -39.39%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-276.75 K
Decreased by -24.99 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00 - 75.37 K -
Increased by +N/A%
-
Jun 30, 21 0.00 - -281.58 M -
Decreased by N/A%
-
Mar 31, 21 0.00 - -6.49 M -
Decreased by N/A%
-
Sep 30, 20 0.00 - -1.10 K -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.